ライフサイエンスコーパス: liver function

1 emoembolization if they still have preserved liver function.

2 c medaka may be mediated through compromised liver function.

3 and low-protein ascites with associated poor liver function.

4 mmatory biomarkers of CVD, but not kidney or liver function.

5 apid lethality despite maintenance of normal liver function.

6 roribose ([(18)F]-2-DFR), for use in imaging liver function.

7 within the Milan criteria and with adequate liver function.

8 tant and conserved regulators in maintaining liver function.

9 ival +/- liver transplant and/or recovery of liver function.

10 t alter levels of markers of liver injury or liver function.

11 use of a lack of specific imaging agents for liver function.

12 tors would play a strong role in maintaining liver function.

13 in by over 30%, showing evidence of improved liver function.

14 during liver growth, and its consequence on liver function.

15 , one single test does not represent overall liver function.

16 ffective in reducing proteinuria and altered liver function.

17 ological hepatocyte apoptosis, which impairs liver function.

18 However, these tests only measure global liver function.

19 el; and had adequate bone marrow, renal, and liver function.

20 rix components and can lead to impairment of liver function.

21 ion of hepatocytes with severe impairment of liver function.

22 n patients with small HCC and well-preserved liver function.

23 ion and cytoplasmic PAP hydrolysis to normal liver function.

24 issues are compatible with impaired renal or liver function.

25 develops as a result of insufficient remnant liver function.

26 and similar results in biochemical assays of liver function.

27 and associated with cholestasis and impaired liver function.

28 f human cytomegalovirus infection is altered liver function.

29 w and is associated with improved markers of liver function.

30 y the extent of the tumor and the underlying liver function.

31 formation without effects on body weight or liver function.

32 h NAFLD or steatohepatitis (NASH) may impair liver function.

33 ncers in highly expressed genes critical for liver function.

34 d positive effects on biochemical markers of liver function.

35 lating metabolic gene expression for optimal liver function.

36 parameters indicative for the improvement of liver function.

37 eosin, Sudan III) were determined to monitor liver function.

38 nduced steatosis in mouse liver and improves liver function.

39 ythrocyte protoporphyrin levels and improved liver function.

40 ped and partially restored mitochondrial and liver function.

41 ding to liver fibrosis, and deterioration of liver function.

42 ulation of hepatic genes with importance for liver function.

43 trastructure of liver and providing enhanced liver function.

44 cells and hepatocytes is a prerequisite for liver function.

45 betaine, and folate) is important for normal liver function.

46 gulate metabolic responses to maintain basic liver functions.

47 eration after surgery and for maintenance of liver functions.

48 e have many alterations in liver biology and liver functions.

49 of critical signaling pathways that control liver functions.

50 without damaging mitochondrial integrity and liver functions.

51 or 1alpha, which are known to be involved in liver functions.

52 ted impaired mitochondrial, peroxisomal, and liver functions.

53 cipe processes, and yielding good phenotypic liver functions.

54 th, protect liver cells, and sustain remnant liver functions.

55 homeostasis and possibly, aggravated loss of liver functions.

56 accumulation have broad effects on metabolic liver functions.

57 s for those with liver dysfunction vs normal liver function, 2016 vs 1510 microg/dL; P = .003).

58 also after implantation in mice with normal liver function, 60% of the time.

59 cell carcinoma (389 [12%]), rash (155 [5%]), liver function abnormalities (165 [5%]), arthralgia (106

60 l dysfunction (11.4% vs 3.3%; P = .006), and liver function abnormalities (8.1% vs 1.6%; P = .01).

61 re less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial

62 All treated recipients had normal liver function after a 6-month follow-up and are well an

63 he liver to regenerate is crucial to protect liver function after injury and during chronic disease.

64 Liver function after stage-1 was assessed using the crit

65 ated that isolated cells are able to restore liver function after transplantation into a cirrhotic li

66 evice that measures two enzymatic markers of liver function (alkaline phosphatase, ALP, and aspartate

67 ell as clinically measured deteriorations in liver function, all point to growing distress in this po

68 Liver function analyses revealed no indication for hepat

69 hepatocytes yields mice that exhibit normal liver function and are indistinguishable from littermate

70 rnatives to liver transplantation to restore liver function and bridge patients to transplantation.

71 using NMP-L provides specific information on liver function and can permit their transplantation whil

72 ncentrated (hemoglobin 16 g/dl), with normal liver function and coagulation testing.

73 lumetry, Doppler ultrasonography, laboratory liver function and damage parameters (nonembolized) live

74 This review provides an overview of normal liver function and development and focuses on the eviden

75 This procedure corrected liver function and eliminated portal hypertension, and t

76 enetic mechanisms associated with markers of liver function and hepatic steatosis, laying the groundw

77 ce, TIMP-1(-/-) mice showed further impaired liver function and histological preservation after IRI.

78 ly decreased, lipid profiles normalized, and liver function and histology were improved.

79 Liver function and immunovirological parameters were mon

80 e present in some patients, including normal liver function and Leigh syndrome (subacute necrotizing

81 ts with multiple intrahepatic tumors or poor liver function and no major comorbidities were listed fo

82 nd late after transplantation in relation to liver function and operational tolerance.

83 and not solely by simultaneous impairment of liver function and performance status.

84 y) can measure both total and future remnant liver function and potentially identify patients at risk

85 severe degenerative phenotype with impaired liver function and premature death.

86 drolase (Fah) deficiency, hiHeps restore the liver function and prolong survival.

87 hat can play an important regulatory role in liver function and provide new insights into the regulat

88 Liver function and regeneration was monitored at 1 to 14

89 splantation lessened liver injury, recovered liver function and rescued the life of Fah-/- mice after

90 ntigen-positive viremic patients with normal liver function and the incorporation of new biomarkers t

91 he effect of the first TACE on parameters of liver function and tumor response and their impact on ov

92 ffect of the treatment on the immune system, liver functions and histology, insulin resistance and li

93 reticulum stress, resulting in impairment of liver functions and, in some cases, hepatocellular carci

94 is contraindicated in patients with impaired liver function, and activated partial thromboplastin tim

95 he lumbar spine and proximal femur (by DXA), liver function, and bone markers were measured at entry

96 ion, including assessment of renal function, liver function, and complete blood count, were within no

97 for demographics, HIV treatment and status, liver function, and immune status, both the prevalence a

98 Single recurrences with preserved liver function, and no portal hypertension were treated

99 Parathyroid hormone, 25-hydroxyvitamin D, liver function, and phosphocalcic tests were measured in

100 score, lung injury, cardiac performance and liver function, and reduced levels of non-transferrin bo

101 pathway, its role in cell-cell adhesion and liver function, and the cell type-specific roles of Wnt/

102 velopment of a paper-based device to measure liver function, and the development of a device to ident

103 All transplanted livers functioned, and serum transaminases, bilirubin, i

104 year, anemia, depression, abnormal renal or liver function, anticonvulsant use, labile international

105 The most important biomarkers for liver function are bilirubin and prothrombin time expres

106 Major liver functions are tightly linked to the 3D assembly of

107 androgen excess, affects maternal and fetal liver function as demonstrated by increased triglyceride

108 Complete blood counts, renal and liver function assessments, previous therapies, pain med

109 r, cholestasis was rare and no difference in liver function at 6 wk was observed.

110 Adverse event profiles and liver function at EOP were similar, although kidney func

111 These patients had better liver function at inclusion than the patients without ep

112 ng the evidence for association of PFOA with liver function at the individual level within water dist

113 Additionally, patients with compromised liver function attributable to diseases, such as cirrhos

114 fety outcomes included invasive candidiasis, liver function, bacterial infection, length of stay, int

115 s a clinically relevant measure of synthetic liver function, based on international normalized ratio

116 recurrence were compared with demographics, liver function, basic immune markers, treatment dose, an

117 After reperfusion, HMP-preserved livers functioned better and showed less hepatocellular

118 encephalopathy 3 months after LT with stable liver function but a severe portal stenosis and the pres

119 st-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood o

120 e a statin is prescribed primarily to assess liver function, but the association with cardiovascular

121 in Zuckers without affecting BW and improved liver function by decreased lipogenesis, increased fatty

122 The impairment of liver function by low environmentally relevant doses of

123 is an extracorporeal procedure that supports liver function by removing endogenous toxins that cause

124 SOCS2 preserves liver function by restraining the first round of hepatoc

125 t in Atp7b(-/-) mice, an animal model of WD, liver function can be significantly improved without cop

126 rrhosis severity: in patients with preserved liver function (Child A), combination therapy is recomme

127 erapy resulted in significant improvement in liver function, coagulation, incidence of encephalopathy

128 feasibility and clear safety, with improved liver function compared with standard static cold storag

129 during and post DEN administration improved liver functions, decreased the levels of MDA, DNA fragme

130 potential for future applications of on-chip liver-function detection.

131 ere identified in blood pressure, adiposity, liver function, drug therapy, symptoms, or quality of li

132 The effects on liver function due to the substitution of original phago

133 The optimum strategy for monitoring liver function during antituberculous therapy is unclear

134 aboration, we identify objective measures of liver function/dysfunction that independently influence

135 al titers in all organs, increased levels of liver function enzymes and blood clotting times, decreas

136 mated glomerular filtration rate (eGFR), and liver function enzymes, annually for 5 years.

137 ellular microenvironment towards stabilizing liver functions for weeks.

138 plex (PIC) formation at post-natal expressed liver function genes and down-regulates a subset of embr

139 sity resulted in significant improvements in liver function, glucose uptake and pancreatic beta-cell

140 Three months after laparotomy, her liver function had recovered, with resolution of her asc

141 Because epigenetic control of liver function has been previously implicated in the reg

142 Analysis of liver function, hepatic regeneration, and comprehensive

143 ine levels, maintenance of normal kidney and liver function, histologic evidence of reduced organ dam

144 sidered upon development of tumor recurrence/liver function impairment.

145 Clinical measures of liver function improved substantially for all patients.

146 Liver function improved: compared with placebo, levels o

147 ces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/

148 d perfluorooctanoic acid (PFOA) exposure and liver function in a Mid-Ohio Valley community.

149 n that stem cell-based therapies can improve liver function in a mouse model of hepatic failure.

150 PFOA and PFOS concentrations with markers of liver function in adults.

151 r failure combines an acute deterioration in liver function in an individual with pre-existing chroni

152 These patients also had improvements in liver function in association with a substantial reducti

153 G) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric patients with non-alcoholic

154 on of HEN enabled weight gain and stabilized liver function in both age groups, but it hardly influen

155 e rates may allow longitudinal monitoring of liver function in disease development.

156 tive, and discriminatory method of assessing liver function in HCC that has been extensively tested i

157 to prevent fibrosis progression and improve liver function in humans.

158 We investigated the role of Flvcr1a in liver function in mice.

159 , which may underlie aberrant metabolism and liver function in obesity.

160 hepatitis B virus (HBV) replication, improve liver function in patients with compensated or decompens

161 d steatohepatitis effectively and to improve liver function in patients with obesity-related NAFLD.

162 motor system pathology, and impair essential liver function in SMA.

163 with progressive deterioration of underlying liver function in terms of Child-Pugh class and MELD sco

164 USPIO did not affect pregnancy outcomes and liver function in the mother and the offspring, suggesti

165 Bile salt synthesis is a specialized liver function in vertebrates.

166 diated nuclear receptor dysfunction disrupts liver function in WD and potentially in other disorders

167 red as a supplementary approach to improving liver function in WD.

168 test, as it can measure multiple aspects of liver function in, specifically, the future remnant live

169 useful PET probe for imaging and quantifying liver functions in vivo, with likely significant clinica

170 n tomography (PET) is rarely used to monitor liver function, in part because of a lack of specific im

171 nuated apoptosis of hepatocytes and improved liver function including lipid metabolism.

172 le exposures were consistent with changes in liver function, including a decline in concentrations of

173 transcription factors are critical for many liver functions, including metabolism, development, and

174 schars, lymphadenopathy, bacteremia, altered liver function, increased WBC counts, pathogen-specific

175 evidenced by histopathology, disturbances in liver function, induction of heat shock protein 70, modu

176 coffee consumption with serum biomarkers of liver function, inflammation, and metabolic health was e

177 monary hypertension, pulmonary inflammation, liver function, inflammatory infiltration, and microinfa

178 sured before a statin prescription to assess liver function is an independent risk factor for CVD and

179 C-mediated removal of copper via kidney when liver function is impaired.

180 reoperative assessment of the future remnant liver function is mandatory in the selection of candidat

181 ular disease (CVD), as well as on kidney and liver function, is unknown.

182 ce have altered liver morphology and altered liver function leading to changes of glucose metabolism

183 e underlying liver cirrhosis and compromised liver function, limiting treatment options.

184 that Zdhhc13 deficiency results in abnormal liver function, lipid abnormalities, and hypermetabolism

185 atile and promising in vitro system to study liver function, liver diseases, drug targets and long-te

186 Liver function markers improved.

187 Mifepristone was well tolerated and improved liver-function markers.

188 Larger tumor burden, poorer residual liver function, more frequent vascular invasion, and dia

189 Liver function, morphology, histochemistry, and fibrotic

190 For patients with abnormal baseline liver function (n = 49 [47%]), liver function tests sign

191 Patients with normal baseline liver function (n = 55 [52%]) maintained similar enzyme

192 biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evide

193 Laboratory tests revealed unremarkable liver function, normal hemoglobin level, and normal amyl

194 Various grades of reduction in liver function occurred within 6 months in 36.5% of pati

195 To test whether the liver function of supv311 is required for viability we u

196 Because of the complexity of liver function, one single test does not represent overa

197 gs suggest that prolonged PP does not hamper liver function or cause liver damage after extended lapa

198 Neither treatment impaired liver function or cholestasis.

199 survival and the majority not adjusting for liver function or lead-time bias.

200 disease; or had one or more abnormalities of liver function, or liver ultrasound, and 24 of these und

201 had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, although a

202 eated human liver specimen maintained stable liver function over the entire perfusion period.

203 repress promoters of three key regulators of liver functions: p53, SIRT1, and PGC1alpha.

204 Liver function parameters normalized after 1 month of tr

205 s observed in the acute study, did not alter liver function parameters, and caused a 50% increase in

206 nalyzed for viral kinetics and for renal and liver function parameters.

207 ly by a combination of conventional tests of liver function, platelet count, and liver ultrasound.

208 able in age, sex, baseline HIV profiles, and liver function profiles.

209 In patients with normal liver function, recurrence was also significantly higher

210 (ECMs) alone yield iHeps with low levels of liver functions relative to adult primary human hepatocy

211 of metabolic diseases; however, its role in liver function remains elusive.

212 ver 60% and associated features include poor liver function, renal failure, refractory shock, and hig

213 Accuracy of in-situ liver function screening was validated by 96 separate te

214 hosis (ie, cirrhosis but preserved synthetic liver function) should receive the same treatment as HCV

215 mean HAS- BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

216 core, HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

217 , and HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predispositi

218 to compare the Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predispositi

219 HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predispositi

220 The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

221 a mean HASBLED (hypertension, abnormal renal/liver function, stroke, bleeding predisposition/history,

222 re based on hypertension, abnormal renal and liver function, stroke, prior major bleeding, labile int

223 ne receptor (CAR or NR1I3) regulates several liver functions such as drug and energy metabolism and c

224 Five (15%) patients had liver function test (LFT) results that were more than ei

225 two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).

226 The liver function test and histological study revealed mini

227 Thyroid and liver function test results were normal, but she had rap

228 ated with patient survival, acute rejection, liver function test results, recurrence of viral or othe

229 cose, and lipid levels, insulin sensitivity, liver function test results, waist circumference, blood

230 y seems to be the most valuable quantitative liver function test, as it can measure multiple aspects

231 ass index (BMI), HBV DNA level, HBsAg level, liver function test, complete blood count, aspartate ami

232 A uniform policy of liver function testing at 2 weeks is useful for prompt i

233 h reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsui

234 tes of infection, rash, and abnormalities on liver-function testing were higher with daclizumab HYP t

235 -related adverse events and abnormalities on liver-function testing were more common with abiraterone

236 mas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [11%]) in the vemurafenib group

237 al blood counts, electrolytes, and renal and liver function tests (including lactic acid dehydrogenas

238 Although liver function tests (LFTs) are routinely measured in pr

239 ther symptom-based screening, screening with liver function tests (LFTs), HCV antibody (Ab) screening

240 (IBD) are frequently associated with altered liver function tests (LFTs).

241 om a brain-death donor was declined for high liver function tests (LFTs).

242 no or minimal hepatic injury who had normal liver function tests (LTs) (referred to herein as the no

243 Inclusion criteria were liver function tests 2.5 times the upper limit of normal

244 re cohort, these miRNAs were correlated with liver function tests and were independent predictors of

245 We further discuss the use of liver function tests as prognostic markers in patients w

246 of a common duct stone (including increased liver function tests but bilirubin <4 mg/dL and no chola

247 Liver function tests decreased from baseline to end of t

248 However, traditional liver function tests do not provide quantitative data ab

249 serum erythrocyte protoporphyrin levels and liver function tests following treatment were assessed.

250 sistance, serum ferritin, lipid profile, and liver function tests improved irrespective of bloodletti

251 , weight, liver size, blood lipids and blood liver function tests of the subjects were measured.

252 Histology studies and liver function tests reveal that no apparent toxicity is

253 y periodic surveillance with hepatic USG and liver function tests scheduled every 6 months for the fi

254 computed tomography volumetry, quantitative liver function tests should be used to determine whether

255 rmal baseline liver function (n = 49 [47%]), liver function tests significantly improved from baselin

256 egorized with NAFLD Activity Score (NAS) and liver function tests were done before surgery and after

257 At EOP, liver function tests were similar but creatinine clearan

258 Reliance on abnormal liver function tests will miss most patients with signif

259 acteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assess

260 NA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient age w

261 ic, pancreatitis, unexplained derangement of liver function tests, and/or dilated CBD without an iden

262 Unit (ICU) and hospital stay, postoperative liver function tests, fatty acid and eicosanoid concentr

263 ied secondary outcomes, including adiposity, liver function tests, incidence of conjugated hyperbilir

264 Passive liver function tests, including biochemical parameters a

265 Postoperative liver function tests, intensive care unit stay, hospital

266 eatment, all patients had improved or normal liver function tests, resolution of C4d deposition and s

267 Dynamic quantitative liver function tests, such as the indocyanine green test

268 NE search was performed using the key words "liver function tests," "functional studies in the liver,

269 ic control, blood pressure, lipid tests, and liver function tests.

270 uence postoperative AST peak values or other liver function tests.

271 difference was found in other postoperative liver function tests.

272 vity of liver disease, which is reflected by liver function tests.

273 te dehydrogenase (LDH), 397 IU/L; and normal liver function tests.

274 stasis had abnormal findings on simultaneous liver function tests.

275 amination to her family doctor with abnormal liver function tests.

276 Adverse events included abnormalities in liver-function tests, fatigue, nausea, headache, dizzine

277 pyrexia, somnolence, and abnormal results on liver-function tests.

278 ceptible to early transient deterioration of liver function than after SG.

279 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and long-term ou

280 y clinical variables including demographics, liver function, tumor characteristics, nature of the sur

281 l survival outcomes are affected by baseline liver function, tumor size, and AFP level.

282 All the patients had at least one abnormal liver-function value; all persistent elevations were gra

283 ned parameters of cholesterol metabolism and liver function values in serum (n = 28) and gallstones (

284 ial evaluation includes determination of the liver function via serum tests and assessment of liver f

285 Liver function was assessed by clearance of indocyanine

286 ood samples were collected and analyzed, and liver function was evaluated.

287 Greatest impact on liver function was found in animals with polymicrobial s

288 for 9 months) initiated post-transplant when liver function was stabilized.

289 Liver function was stable in all patients, although reve

290 In contrast, full restoration of liver functions was found in the normal group with the s

291 rogressed on sorafenib, and had Child-Pugh A liver function were enrolled.

292 on in all individuals, and no differences in liver function were observed in individuals with a liver

293 ithin the Milan criteria (MC), 138 with good liver function were resected (LR group) from a perspecti

294 rmal level, while total bilirubin (TBIL) and liver function were significantly improved.

295 Serum markers of liver function were used to evaluate LR and liver dysfun

296 d systemic inflammation, and, in men, poorer liver function, which is a marker of high alcohol consum

297 s 0 or 1, adequate respiratory, cardiac, and liver function, white blood cell count at least 3 x 10(9

298 stages of disease, including improvement in liver function with hepatic "recompensation," reduction

299 ets being both deleterious and beneficial to liver function; with increasingly novel methods of manip

300 ted hyperglycemia induce multiple changes in liver function, yet we know little about the role played